Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Humacyte, Inc.

HUMA · Nasdaq · CIK 0001818382 · Healthcare · Biotechnology

INSIDER SIGNAL

48.8 / 100

3 buyers · 5 purchase transaction lines · $90.0K gross purchase

WHY THIS SIGNAL?

Buyer breadthModerate
Purchase sizeLow
RoleStrong
RecencyModerate
ConvictionLow
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+21.0 / 35
Purchase size+1.3 / 25
Role+20.0 / 20
Recency+5.7 / 10
Conviction+0.8 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 3 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Buying conviction is reduced by concurrent selling
  • ✓ Role scores high · most senior buyer: Director

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Jones Keith AnthonyDirector
●●●
Sebelius KathleenDirector
●
Constantino Michael T.Director
●
Sander Dale A.CFO and Chief Corp. Dev. Off
▼
Parikh Shamik JChief Medical Officer
▼
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS3
PURCHASE CONCENTRATION56%Largest buyer: Sebelius Kathleen · $50.0K
CLUSTER BUYING · 15D2 insidersPeak activity: 2026-05-18–2026-05-19

Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

48.8 / 100

Latest recorded score

↓ -0.2 ptsversus the previous recorded snapshot
  1. 49.2
  2. 49.2
  3. 49.1
  4. 49.0
  5. 48.8

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

5Purchases
2Sales
2Other Form 4 lines
9SEC filings · 365 days
BUYING5 qualifying P line(s) · 180 days
SELLING2 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-28.6%
3M
-41.4%
6M
-37.2%
12M
-76.0%

Volatility & liquidity

Volatility
112.5%
Beta
—
Avg daily value
USD 2.5M

Valuation

Market cap
USD 112.5M
P/E
—

Fundamentals

Profit margin
—
ROE
-1313.4%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-10 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
29,399,293
Previous report
31,807,566
Avg daily volume
4,024,163
Days to cover
7.3

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-14Jones Keith AnthonyPurchase (P)Common Stock10,000USD 0.56USD 5,600SEC filing ↗
2026-08-20Jones Keith AnthonyPurchase (P)Common Stock10,000USD 0.69USD 6,900SEC filing ↗
2026-08-17Jones Keith AnthonyPurchase (P)Common Stock30,000USD 0.59USD 17,700SEC filing ↗
2026-05-19Sebelius KathleenPurchase (P)Common Stock56,818USD 0.88USD 50,000SEC filing ↗
2026-05-18Constantino Michael T.Purchase (P)Common Stock11,000USD 0.89USD 9,790SEC filing ↗
2025-04-14Scheessele William JohnPurchase (P)Common Stock6,493USD 1.54USD 9,999SEC filing ↗
2025-04-10Sander Dale A.Purchase (P)Common Stock20,000USD 1.53USD 30,600SEC filing ↗
2025-04-10Parikh Shamik JPurchase (P)Common Stock7,500USD 1.55USD 11,625SEC filing ↗
2025-04-08Sebelius KathleenPurchase (P)Common Stock50,000USD 1.32USD 66,000SEC filing ↗
2025-04-08Green Charles BrucePurchase (P)Common Stock6,000USD 1.29USD 7,740SEC filing ↗
2025-04-07Constantino Michael T.Purchase (P)Common Stock16,000USD 1.26USD 20,160SEC filing ↗
2024-12-04Constantino Michael T.Purchase (P)Common Stock4,600USD 4.39USD 20,194SEC filing ↗
2024-11-19Niklason Laura EPurchase (P)Common Stock1,797USD 4.44USD 7,979SEC filing ↗
2024-11-19Dougan Brady WPurchase (P)Common Stock1,797USD 4.44USD 7,979SEC filing ↗
2024-08-29Niklason Laura EPurchase (P)Common Stock1,222USD 6.55USD 8,004SEC filing ↗

Form 4 evidence

9 transaction lines in the latest 365-day window; 164 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-14Jones Keith AnthonyPurchase (P)Common Stock10,000USD 0.56USD 5,600SEC filing ↗
2026-08-20Jones Keith AnthonyPurchase (P)Common Stock10,000USD 0.69USD 6,900SEC filing ↗
2026-08-17Jones Keith AnthonyPurchase (P)Common Stock30,000USD 0.59USD 17,700SEC filing ↗
Show recent Form 4 evidence (9 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-14Jones Keith AnthonyPurchase (P)Common Stock10,000USD 0.56USD 5,600SEC filing ↗
2026-08-20Jones Keith AnthonyPurchase (P)Common Stock10,000USD 0.69USD 6,900SEC filing ↗
2026-08-17Jones Keith AnthonyPurchase (P)Common Stock30,000USD 0.59USD 17,700SEC filing ↗
2026-05-19Sebelius KathleenPurchase (P)Common Stock56,818USD 0.88USD 50,000SEC filing ↗
2026-05-18Sander Dale A.Sale (S)Common Stock45,887USD 0.90USD 41,298SEC filing ↗
2026-05-18Parikh Shamik JSale (S)Common Stock45,887USD 0.90USD 41,298SEC filing ↗
2026-05-18Constantino Michael T.Purchase (P)Common Stock11,000USD 0.89USD 9,790SEC filing ↗
2025-11-16Sander Dale A.Award / grant (A)Common Stock311,100USD 0.00USD 0SEC filing ↗
2025-11-16Parikh Shamik JAward / grant (A)Common Stock311,100USD 0.00USD 0SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerHUMA
CIK0001818382
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history164 transaction lines from 2020-09-22 to 2026-09-14
44 P purchase lines · 90 S sale lines · 30 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.